

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 12, 2021

**BioSig Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38659**  
(Commission File Number)

**26-4333375**  
(IRS Employer  
Identification No.)

**54 Wilton Road, 2nd Floor**  
**Westport, Connecticut**  
(Address of principal executive offices)

**06880**  
(Zip Code)

**(203) 409-5444**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of exchange on which registered</u>
Common Stock, par value \$0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 7.01 Regulation FD Disclosure.**

On April 12, 2021, Kenneth L. Londoner, Chairman and Chief Executive Officer of BioSig Technologies, Inc. (the “Company”), is expected to make a presentation regarding the Company at the Annual Needham Virtual Healthcare Conference at 3:00 PM ET. The slide presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. Additionally, the Company may, from time to time, to present and/or distribute to the investment community and utilize the slide presentation at various industry and other conferences. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Slide Presentation of BioSig Technologies, Inc., April 2021</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **BIOSIG TECHNOLOGIES, INC.**

Date: April 12, 2021

By: /s/ Kenneth L. Londoner  
Name: Kenneth L. Londoner  
Title: Executive Chairman



**BioSig**<sup>™</sup>  
technologies

20<sup>th</sup> Annual Needham Virtual Healthcare Conference

NASDAQ: BSGM

# Disclaimer

---

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.



# Who We Are – NASDAQ: BSGM



- EP Tech Market estimated 13.5% CAGR
- Global EP Market Expected to be \$12.2 Billion by 2026
- 34 Patents Issued or Allowed
- First customer #1 center by volume in the U.S.
- Second customer voted #1 hospital in the world
- Razor & Blade Business Model
- FDA Cleared
- Unblinding of clinical data in 2021 expected



Data source: MarketWatch Global Electrophysiology Device Market Could Exceed \$12.2 Billion By 2026. Definitive Healthcare, U.S. News & World Report and Newsweek.

SYMBOL: BSGM | 3

# Our Solution

---



More information, better decisions™

- **Signal processing platform**
- **Intracardiac signals**
- **Customizable interface**
- **Artificial intelligence**



# “Secret Sauce”

## Optimize signals for mapping, signal interpretation and during therapy delivery

- Right Atrial Typical Flutter signals during ablation with optimized settings showing no RF noise and detailed signal attenuation





## Global EP Procedures Growing Rapidly

Cardiac Ablation Procedures Are Key Hospital Revenue Drivers

Complex Cardiac Ablation:  
**13.5% Growth Rate**  
(Estimated)

U.S.  
**3,425**  
EP labs

OUS:  
**3,915**  
EP labs

Total Global Addressable Market  
**\$2.0 Billion**



**BioSig**  
technologies

Published by Cardiovascular Rounds, Guggenheim Analyst – Chris Pasquale  
Data source: 2018 MD&D report Advisory Board and BioSig Technologies, Inc. estimates.

SYMBOL: BSGM | 6


# Expanded Product Adoption, Experience, and a Growing Database

# PURE EP Procedures by Account	
Texas Cardiac Arrhythmia Institute - Austin	293
Mayo Clinic	120
UNIV of Penn	99
Mass General	13
Deborah Heart & Lung	61
Overland Park - Kansas	62
Memorial – South Bend, IN	28
Houston Methodist	31
First in-human - TX, IN, SC	20
<b>TOTAL</b>	<b>727</b>

\*Data as of 04/02/21

# Physician Users	
TCAI	10
Mayo	3
Penn	13
MGH	1
Deborah	2
Overland Park	4
Memorial	2
Houston Methodist	2
First in-human - TX, IN, SC	4
<b>TOTAL</b>	<b>41</b>

Diagnosis	# of Cases
Paroxysmal AF	222
Persistent AF	183
Ventricular Tachycardias and PVCs	132
SVTs	68



# PURE EP™ System – Customer Installations



Hospital of the  
University of Pennsylvania




PURE EP™



Texas Cardiac Arrhythmia Institute

# Business Model

---



# Commercialization – Regions and Centers of Excellence



## Florida

120 EP Programs  
240 Labs

## Texas

220 EP Programs  
440 Labs

## Northeast

175 EP Programs  
400 Labs

## Revenue Potential

\$286 Million



Source: Industry data and BioSig Technologies, Inc. estimates. Green pins denote installations. Blue pins denote expected upcoming installations.

SYMBOL: BSGM | 10




# Highly Profitable Elective Procedure

## EP procedures are clinically urgent

- Delaying procedure increases stroke risk and worsens outcomes

## EP is revenue generating

- CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines





# Clinical Data Catalysts

---

Further establish the safety and effectiveness of the PURE EP™ System

Multi-center: **Mayo Clinic, Mass General, TCAI**

Enrollment Completion	<b>April 13, 2021*</b>
Abstract Acceptance	<b>Q2, 2021*</b>
Unblinding data to the public	<b>July 15, 2021*</b>
Heart Rhythm Society Presentation	<b>July 27, 2021*</b>



\*These are expected dates.

ClinicalTrials.gov Identifier: NCT04112433

SYMBOL: BSGM | 12

# Physician Testimonies



"The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future."

- K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic



"The quality of the recording that we can get in the lab can make a big difference [during the procedure]. . . The PURE EP System clearly gave us better quality of intracardiac recording [compared to conventional systems.]"

- Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute



# Market Value Inflection


Company	Market Capitalization (in millions USD)				
<b>BioSig Technologies</b> Formed 2009/IPO 2014	\$140				
<b>Axonics Modulation</b> Formed 2012/IPO 2018	\$405	\$620	x	\$2,200	
<b>Acutus Medical</b> Formed 2011/IPO 2020	x	\$670			
<b>Nevro Corp</b> Formed 2006/IPO 2014	x	x	\$1,090	\$1,623	\$2,740
<b>Stereotaxis</b> Formed 1990/IPO 2004	x	x	\$1,028	\$1,756	\$3,105
<b>Revenues</b> (millions USD)	≈\$1m	≈\$15m	≈\$30m	≈\$50m	≈\$100m



Source: FactSet Systems and BioSig Technologies' estimates. Market cap and revenues in millions.

SYMBOL: BSGM | 14

# Revenue Increase = Market Capitalization Increase



# Management Team



**Kenneth L. Londoner, MBA**  
Founder, Chairman, CEO, Director  
NeuroClear Technologies; Endicott Management Partners;  
J & W Seligman & Co.



**Steve Chaussy, CPA**  
CFO  
NeuroClear Technologies; Liberski Inc; Anna & Co; Penske Automotive;  
Ford Hogg and Cobbe



**Brenda Castrodad**  
Director of Human Resources  
TissueTech, Inc.; HeartWare, Inc.; Schering-Plough Corp



**Andy Ballou**  
Vice President, Investor Relations  
Janney Montgomery Scott; RBC Capital Markets



**Julie Stephenson, BSN, MBA**  
Vice President, Clinical Affairs  
Medtronic; Boston Scientific; Guidant Corporation



**Manasi Patwardhan**  
Director of Strategic Planning Verily Life Sciences,  
Boston Scientific- Neuromodulation; Medtronic



**Natasha Drapeau**  
Executive Vice President  
NeuroClear Technologies; Alliance for Advancing Bioelectronic  
Medicine; Institute of Directors, UK; IG Group Plc, UK



**Barry Keenan, Ph.D, MBA, PMP**  
Vice President, Engineering  
Medtronic; Nexxon MedSystems; Alfred Mann Institute for Biomedical Engineering;  
Alfred Mann Foundation for Scientific Research



**Todd Wiltshire**  
Senior Vice President, Corporate Development  
Fidelity Investments; Credit Agricole; UBS; Morgan Stanley



**John Kowalski**  
Vice President, Sales  
Biosense Webster (Johnson & Johnson)



**Olivier Chaudoir**  
Senior Director, Marketing  
Biosense Webster; DePuy Synthes



**Ewald Riechert**  
Director of Regulatory Affairs / Quality Assurance  
TUV Rheinland, Siemens, Acclarent, Inc. (J&J Company)



# Value Drivers

- \$28 million\* in cash on the balance sheet and no debt
- Expect to triple the customer base in 2021
- Targeting sequential revenue growth in 2021
- Expect CE mark approval / EU entry 2022
- Launched AI program – Mayo partnership
- Expect presentation of data Q3 2021



 **Nasdaq : BSGM**